RxDoctor Payments Data

Tedla Anbessie, MD

Internal Medicine · Alexandria, VANPI 1972590743

Payments from drug & device makers

$4,176in general payments, 2019–2025

Across 225 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$513
  • Amgen$391
  • AstraZeneca$378
  • AbbVie$311
  • Astellas Pharma US Inc$250
  • Lilly USA, LLC$243
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,06097%
  • Education$1002%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,176 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$175,788
Medicare patients
542
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$105,390
TrulicityDulaglutide88$88,075
OzempicSemaglutide56$57,548
JardianceEmpagliflozin81$51,689
XifaxanRifaximin27$41,514
XareltoRivaroxaban79$30,873
FarxigaDapagliflozin Propanediol69$29,635
JanuviaSitagliptin Phosphate27$27,698
JanumetSitagliptin Phos/Metformin Hcl15$22,380
EntrestoSacubitril/Valsartan62$22,238
LinzessLinaclotide19$19,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,096
Atorvastatin Calcium570$8,150
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$8,081
Pantoprazole Sodium171$7,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$105,390220 claims
Lilly USA, LLCTrulicity$243$88,07588 claims
Novo NordiskOzempic$513$57,54856 claims
MerckJanuvia, Janumet$97$50,07842 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$147$41,51427 claims
AstraZenecaFarxiga, Symbicort$378$32,36680 claims
Johnson & JohnsonXarelto$177$30,87379 claims
NovartisEntresto$208$22,23862 claims
AbbVieLinzess$311$19,50819 claims
GSKTrelegy Ellipta$149$18,09626 claims
Astellas Pharma US IncMyrbetriq$250$3,67416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →